Nanomedicine

Lipid nanoparticles, polymeric carriers and inorganic nanoparticles enable precision drug delivery with multiple approved products. The session covers organ-targeted LNPs (lung, CNS, heart) beyond hepatic delivery, PROTAC nanoparticle delivery, immune-modulating nanoparticles for tolerance induction, antibody-drug conjugate intersection with nanocarriers, lipid nanoparticle manufacturing scale-up, and the regulatory pathway under FDA Nanotechnology Task Force. Discussion addresses nanoparticle pharmacokinetics and tissue distribution, inorganic nanoparticles for imaging and therapy (theranostics), the safety considerations around nanoparticle clearance and accumulation, and the manufacturing economics of nanoparticle-based therapies.